CRESCENT BIOPHARMA, INC. Operating Expenses
CRESCENT BIOPHARMA, INC. (CBIO) reported Operating Expenses of $28.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. operating expenses for the quarter ending 2026-06-30 was $28.13M, a 33.78% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating expenses for the quarter ending 2026-03-31 was $25.77M, a 81.16% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating expenses for the quarter ending 2025-12-31 was $102.34M, a 495.29% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating expenses for the quarter ending 2025-09-30 was $25.89M, a 130.42% increase year-over-year.
- CRESCENT BIOPHARMA, INC. operating expenses for fiscal 2025 was $163.48M, a 308.29% increase from fiscal 2024.
- CRESCENT BIOPHARMA, INC. operating expenses for fiscal 2024 was $40.04M, a 1.92% increase from fiscal 2023.
- CRESCENT BIOPHARMA, INC. operating expenses for fiscal 2023 was $39.29M, a 17.26% decline from fiscal 2022.
- CRESCENT BIOPHARMA, INC. operating expenses for fiscal 2022 was $47.48M, a 26.51% decline from fiscal 2021.
| Period end | Operating Expenses 0 month | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28.13M 10-Q · filed 2026-07-30 | $53.90M 10-Q · filed 2026-07-30 | $156.24M derived: sum of 3 quarters · filed 2026-07-30 | $182.12M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2026-03-31 | $25.77M 10-Q · filed 2026-04-29 | $128.10M derived: sum of 2 quarters · filed 2026-04-29 | $153.99M derived: sum of 3 quarters · filed 2026-04-29 | $175.02M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-12-31 | $102.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $128.22M derived: sum of 2 quarters · filed 2026-02-26 | $149.25M derived: sum of 3 quarters · filed 2026-07-30 | $163.48M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $25.89M 10-Q · filed 2025-11-06 | $46.91M derived: sum of 2 quarters · filed 2026-07-30 | $61.14M 10-Q · filed 2025-11-06 | $78.33M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $21.03M 10-Q · filed 2026-07-30 | $35.26M 10-Q · filed 2026-07-30 | $52.45M derived: sum of 3 quarters · filed 2026-07-30 | $63.68M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $14.22M 10-Q · filed 2026-04-29 | $2.40M 10-Q · filed 2025-05-14 | $31.41M derived: sum of 2 quarters · filed 2026-04-29 | $42.65M derived: sum of 3 quarters · filed 2026-04-29 | $53.01M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-12-31 | $17.19M 10-K · filed 2026-02-26 | $28.42M derived: sum of 2 quarters · filed 2026-02-26 | $38.78M derived: sum of 3 quarters · filed 2026-02-26 | $40.04M 10-K · filed 2025-02-13 | ||
| 2024-09-30 | $2.63M 10-Q · filed 2025-11-06 | $11.23M 10-Q · filed 2024-11-13 | $21.59M derived: sum of 2 quarters · filed 2024-11-13 | $32.71M 10-Q · filed 2024-11-13 | $42.31M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-06-30 | $10.36M 10-Q · filed 2024-08-08 | $21.47M 10-Q · filed 2024-08-08 | $31.07M derived: sum of 3 quarters · filed 2025-05-14 | $40.89M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2024-03-31 | $11.12M 10-Q · filed 2025-05-14 | $20.72M derived: sum of 2 quarters · filed 2025-05-14 | $30.53M derived: sum of 3 quarters · filed 2025-05-14 | $39.46M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $19.41M derived: sum of 2 quarters · filed 2025-02-13 | $28.34M derived: sum of 3 quarters · filed 2025-02-13 | $39.29M 10-K · filed 2025-02-13 | ||
| 2023-09-30 | $9.81M 10-Q · filed 2024-11-13 | $18.74M derived: sum of 2 quarters · filed 2024-11-13 | $29.68M 10-Q · filed 2024-11-13 | $40.31M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $8.93M 10-Q · filed 2024-08-08 | $19.87M 10-Q · filed 2024-08-08 | $30.49M derived: sum of 3 quarters · filed 2024-08-08 | $39.26M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $10.94M 10-Q · filed 2024-05-09 | $21.56M derived: sum of 2 quarters · filed 2024-05-09 | $30.33M derived: sum of 3 quarters · filed 2024-05-09 | $43.76M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $10.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $19.39M derived: sum of 2 quarters · filed 2024-03-27 | $32.82M derived: sum of 3 quarters · filed 2024-03-27 | $47.48M 10-K · filed 2024-03-27 | ||
| 2022-09-30 | $8.77M 10-Q · filed 2023-11-03 | $22.20M derived: sum of 2 quarters · filed 2023-11-03 | $36.86M 10-Q · filed 2023-11-03 | $54.30M derived: sum of 4 quarters · filed 2024-03-27 | ||
| 2022-06-30 | $13.43M 10-Q · filed 2023-08-02 | $28.09M 10-Q · filed 2023-08-02 | $45.53M derived: sum of 3 quarters · filed 2024-03-27 | $62.96M derived: sum of 4 quarters · filed 2024-03-27 | ||
| 2022-03-31 | $14.66M 10-Q · filed 2023-05-03 | $32.10M derived: sum of 2 quarters · filed 2024-03-27 | $49.53M derived: sum of 3 quarters · filed 2024-03-27 | $63.93M derived: sum of 4 quarters · filed 2024-03-27 | ||
| 2021-12-31 | $17.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $34.87M derived: sum of 2 quarters · filed 2024-03-27 | $49.27M derived: sum of 3 quarters · filed 2024-03-27 | $64.61M 10-K · filed 2024-03-27 | ||
| 2021-09-30 | $17.42M 10-Q · filed 2022-11-09 | $31.83M derived: sum of 2 quarters · filed 2022-11-09 | $47.16M 10-Q · filed 2022-11-09 | $62.89M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-06-30 | $14.40M 10-Q · filed 2022-08-03 | $29.74M 10-Q · filed 2022-08-03 | $45.47M derived: sum of 3 quarters · filed 2023-03-29 | $60.20M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2021-03-31 | $15.34M 10-Q · filed 2022-04-28 | $31.07M derived: sum of 2 quarters · filed 2023-03-29 | $45.79M derived: sum of 3 quarters · filed 2023-03-29 | $59.90M derived: sum of 4 quarters · filed 2023-03-29 | ||
| 2020-12-31 | $15.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $30.46M derived: sum of 2 quarters · filed 2023-03-29 | $44.56M derived: sum of 3 quarters · filed 2023-03-29 | $61.67M 10-K · filed 2023-03-29 | ||
| 2020-09-30 | $14.73M 10-Q · filed 2021-11-02 | $28.83M derived: sum of 2 quarters · filed 2021-11-02 | $45.94M 10-Q · filed 2021-11-02 | $61.28M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2020-06-30 | $14.11M 10-Q · filed 2021-08-05 | $31.21M 10-Q · filed 2021-08-05 | $46.55M derived: sum of 3 quarters · filed 2022-03-03 | $60.65M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2020-03-31 | $17.11M 10-Q · filed 2021-05-03 | $32.44M derived: sum of 2 quarters · filed 2022-03-03 | $46.55M derived: sum of 3 quarters · filed 2022-03-03 | $63.36M derived: sum of 4 quarters · filed 2022-03-03 | ||
| 2019-12-31 | $15.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $29.44M derived: sum of 2 quarters · filed 2022-03-03 | $46.26M derived: sum of 3 quarters · filed 2022-03-03 | $61.39M 10-K · filed 2022-03-03 | ||
| 2019-09-30 | $14.11M 10-Q · filed 2020-11-06 | $30.92M derived: sum of 2 quarters · filed 2020-11-06 | $46.05M 10-Q · filed 2020-11-06 | $61.01M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-06-30 | $16.82M 10-Q · filed 2020-07-31 | $31.95M 10-Q · filed 2020-07-31 | $46.91M derived: sum of 3 quarters · filed 2021-03-02 | $59.43M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2019-03-31 | $15.13M 10-Q · filed 2020-05-01 | $30.09M derived: sum of 2 quarters · filed 2021-03-02 | $42.61M derived: sum of 3 quarters · filed 2021-03-02 | $54.76M derived: sum of 4 quarters · filed 2021-03-02 | ||
| 2018-12-31 | $14.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $27.48M derived: sum of 2 quarters · filed 2021-03-02 | $39.63M derived: sum of 3 quarters · filed 2021-03-02 | $51.50M 10-K · filed 2021-03-02 | ||
| 2018-09-30 | $12.52M 10-Q · filed 2019-11-07 | $24.67M derived: sum of 2 quarters · filed 2019-11-07 | $36.54M 10-Q · filed 2019-11-07 | $46.35M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2018-06-30 | $12.15M 10-Q · filed 2018-08-09 | $24.03M 10-Q · filed 2019-08-01 | $33.83M derived: sum of 3 quarters · filed 2020-02-28 | $42.02M derived: sum of 4 quarters · filed 2020-02-28 | ||
| 2018-03-31 | $12.15M 10-Q · filed 2019-08-01 | $11.88M 10-Q · filed 2018-05-03 | $21.68M derived: sum of 2 quarters · filed 2020-02-28 | $29.87M derived: sum of 3 quarters · filed 2020-02-28 | $38.11M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $17.72M derived: sum of 2 quarters · filed 2020-02-28 | $25.96M derived: sum of 3 quarters · filed 2020-02-28 | $33.93M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | $8.18M 10-Q · filed 2018-11-02 | $16.43M derived: sum of 2 quarters · filed 2018-11-02 | $24.40M 10-Q · filed 2018-11-02 | $32.75M derived: sum of 4 quarters · filed 2019-03-06 | ||
| 2017-06-30 | $8.24M 10-Q · filed 2018-08-09 | $16.21M 10-Q · filed 2018-08-09 | $24.57M derived: sum of 3 quarters · filed 2019-03-06 | $32.48M derived: sum of 4 quarters · filed 2019-03-06 | ||
| 2017-03-31 | $7.97M 10-Q · filed 2018-05-03 | $16.33M derived: sum of 2 quarters · filed 2019-03-06 | $24.23M derived: sum of 3 quarters · filed 2019-03-06 | $32.33M derived: sum of 4 quarters · filed 2019-03-06 | ||
| 2016-12-31 | $8.36M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $16.26M derived: sum of 2 quarters · filed 2019-03-06 | $24.36M derived: sum of 3 quarters · filed 2019-03-06 | $31.93M 10-K · filed 2019-03-06 | ||
| 2016-09-30 | $7.91M 10-Q · filed 2017-11-08 | $16.00M derived: sum of 2 quarters · filed 2017-11-08 | $23.57M 10-Q · filed 2017-11-08 | $32.50M derived: sum of 4 quarters · filed 2018-03-06 | ||
| 2016-06-30 | $8.09M 10-Q · filed 2017-08-03 | $15.67M 10-Q · filed 2017-08-03 | $24.59M derived: sum of 3 quarters · filed 2018-03-06 | $31.76M derived: sum of 4 quarters · filed 2018-03-06 | ||
| 2016-03-31 | $7.58M 10-Q · filed 2017-05-08 | $16.50M derived: sum of 2 quarters · filed 2018-03-06 | $23.67M derived: sum of 3 quarters · filed 2018-03-06 | $33.32M derived: sum of 4 quarters · filed 2018-03-06 | ||
| 2015-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $16.09M derived: sum of 2 quarters · filed 2018-03-06 | $25.74M derived: sum of 3 quarters · filed 2018-03-06 | $32.86M 10-K · filed 2018-03-06 | ||
| 2015-09-30 | $7.17M 10-Q · filed 2016-11-04 | $16.82M derived: sum of 2 quarters · filed 2016-11-04 | $23.93M 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | $9.65M 10-Q · filed 2016-08-04 | $16.76M 10-Q · filed 2016-08-04 | ||||
| 2014-12-31 | $26.17M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |